Terms: = Uterine cancer AND uPA AND Treatment
111 results:
1. Ulipristal acetate, a selective progesterone receptor modulator, induces cell death via inhibition of STAT3/CCL2 signaling pathway in uterine sarcoma.
Hwang JR; Cho YJ; Ryu JY; Choi JY; Choi JJ; Sa JK; Kim HS; Lee JW
Biomed Pharmacother; 2023 Dec; 168():115792. PubMed ID: 37924789
[TBL] [Abstract] [Full Text] [Related]
2. Effects of long-term intermittent pharmacological therapy with ulipristal acetate on reducing the volume of uterine fibroids and relieving symptoms.
Kyeong HK; Choi J; Na YJ; Kim HG
Minerva Obstet Gynecol; 2023 Jun; 75(3):236-242. PubMed ID: 36786781
[TBL] [Abstract] [Full Text] [Related]
3. The Potential of Transforming Growth Factor-beta Inhibitor and Vascular Endothelial Growth Factor Inhibitor as Therapeutic Agents for uterine Leiomyoma.
Park JY; Chae B; Kim MR
Int J Med Sci; 2022; 19(12):1779-1786. PubMed ID: 36313223
[No Abstract] [Full Text] [Related]
4. Evaluation of marketing authorization and clinical implementation of ulipristal acetate for uterine fibroids.
Middelkoop MA; de Lange ME; Clark TJ; Mol BWJ; Bet PM; Huirne JAF; Hehenkamp WJK
Hum Reprod; 2022 May; 37(5):884-894. PubMed ID: 35143669
[TBL] [Abstract] [Full Text] [Related]
5. Phase III long-term study to evaluate the efficacy and safety of ulipristal acetate in Japanese patients with uterine fibroids.
Osuga Y; Nakano Y; Yamauchi Y; Murakawa H
J Obstet Gynaecol Res; 2021 Sep; 47(9):3269-3278. PubMed ID: 34109697
[TBL] [Abstract] [Full Text] [Related]
6. Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up.
Nicolás I; Martínez-Zamora MÁ; Gracia M; Carrion A; Feixas G; Bernal L; Quintas L; Rius M; Castelo-Branco C; Carmona F
Gynecol Endocrinol; 2021 Sep; 37(9):831-835. PubMed ID: 34044726
[TBL] [Abstract] [Full Text] [Related]
7. Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications.
Gomes FG; Almeida VH; Martins-Cardoso K; Martins-Dinis MMDC; Rondon AMR; Melo AC; Tilli TM; Monteiro RQ
Braz J Med Biol Res; 2021; 54(6):e10754. PubMed ID: 33886813
[TBL] [Abstract] [Full Text] [Related]
8. Management of women with uterine fibroids in reproductive center: retrospective analysis of clinical and reproductive outcomes.
Miriello D; Galanti F; Meneghini C; Fabiani C; Dal Lago A; Schiavi MC; Rago R
Minerva Obstet Gynecol; 2022 Apr; 74(2):130-136. PubMed ID: 33876897
[TBL] [Abstract] [Full Text] [Related]
9. The endometrial response to modulation of ligand-progesterone receptor pathways is reversible.
Chodankar RR; Murray A; Nicol M; Whitaker LHR; Williams ARW; Critchley HOD
Fertil Steril; 2021 Sep; 116(3):882-895. PubMed ID: 33865567
[TBL] [Abstract] [Full Text] [Related]
10. Nutraceuticals in fibroid management after ulipristal acetate administration: An observational study on patients' compliance.
Tinelli A; Gustapane S; D'Oria O; Licchelli M; Panese G
Int J Gynaecol Obstet; 2022 Jan; 156(1):133-138. PubMed ID: 33797759
[TBL] [Abstract] [Full Text] [Related]
11. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
[TBL] [Abstract] [Full Text] [Related]
12. Use of Ulipristal Acetate and Risk of Liver Disease: A Nationwide Cohort Study.
Yoon EL; Yuk JS
J Clin Endocrinol Metab; 2021 May; 106(6):1773-1782. PubMed ID: 33567071
[TBL] [Abstract] [Full Text] [Related]
13. Medical Therapy for Fibroids: What Next for Ulipristal Acetate?
Ekanem E; Talaulikar V
Adv Ther; 2021 Jan; 38(1):137-148. PubMed ID: 33201387
[TBL] [Abstract] [Full Text] [Related]
14. A multi-centre, randomized, non-inferiority trial to compare ulipristal with standard surgical treatment in women with symptomatic uterine fibroids: Protocol of the MYOMEX-2 trial.
Middelkoop MA; Huirne JAF; van der Weide MCJ; Bosmans JE; Hehenkamp WJK;
Eur J Obstet Gynecol Reprod Biol; 2021 Jan; 256():63-69. PubMed ID: 33171419
[TBL] [Abstract] [Full Text] [Related]
15. treatment Choices in a National Cohort of Canadian Women With Symptomatic uterine Fibroids.
Strand T; Kives S; Leyland N; Ashkenas J; Janiszewski P; Thiel J
J Obstet Gynaecol Can; 2020 Dec; 42(12):1475-1482.e2. PubMed ID: 33046429
[TBL] [Abstract] [Full Text] [Related]
16. Hysteroscopic and ultrasonographic evaluation of ulipristal acetate treatment for symptomatic myomas in premenopausal women: a prospective study.
De Franciscis P; Schiattarella A; Riemma G; Labriola D; Ambrosio D; Vitale SG; Cianci A; Cucinella G; Calagna G; Colacurci N
Minim Invasive Ther Allied Technol; 2022 Mar; 31(3):435-440. PubMed ID: 33043778
[TBL] [Abstract] [Full Text] [Related]
17. Liver Injury with Ulipristal Acetate: Exploring the Underlying Pharmacological Basis.
Gatti M; Poluzzi E; De Ponti F; Raschi E
Drug Saf; 2020 Dec; 43(12):1277-1285. PubMed ID: 32748236
[TBL] [Abstract] [Full Text] [Related]
18. Suspension of ulipristal acetate for uterine fibroids during ongoing EMA's review of liver injury risk: Unfortunate timing during the Covid-19 pandemic!
Rozenberg S; Revercez P; Fastrez M; Vandromme J; Bucella D
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():300-302. PubMed ID: 32650189
[TBL] [Abstract] [Full Text] [Related]
19. Ulipristal acetate versus gonadotropin-releasing hormone agonists prior to laparoscopic myomectomy (MYOMEX trial): Long term results of a double-blind randomized controlled trial.
De Milliano I; Middelkoop MA; Huirne JAF; Kwee J; Geomini PMAJ; Schoot BC; Van Baal M; Bosmans JE; Hehenkamp WJK
Eur J Obstet Gynecol Reprod Biol; 2020 Sep; 252():256-264. PubMed ID: 32634673
[TBL] [Abstract] [Full Text] [Related]
20. Ulipristal acetate before in vitro fertilization: efficacy in infertile women with submucous fibroids.
Morgante G; Centini G; Troìa L; Orvieto R; De Leo V
Reprod Biol Endocrinol; 2020 May; 18(1):50. PubMed ID: 32430027
[TBL] [Abstract] [Full Text] [Related]
[Next]
